{"title":"小剂量艾氯胺酮预处理对依托咪酯所致肌阵挛的影响:一项随机对照试验。","authors":"Liangliang Gao, Xinyu Lu, Aiping Tan, Jiaying Liufu, Yidan Xu, Lei Wei","doi":"10.2147/DDDT.S495130","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Etomidate has been observed to precipitate myoclonus in patients undergoing induction of general anaesthesia. This study was designed to investigate the effect of pretreatment with a small dose of esketamine on the incidence of myoclonus induced by etomidate.</p><p><strong>Methods: </strong>One hundred adult patients, who were scheduled to undergo selective operations with general anesthesia, were randomly divided into two groups, with one group receiving esketamine (Group E) and the other receiving normal saline (Group C). The group receiving esketamine (Group E) was administered an injection of 0.15 mg/kg of esketamine, while the control group (Group C) was given an equivalent volume of normal saline two minutes before the administration of 0.3 mg/kg of etomidate. The primary objective was to determine the incidence of etomidate-induced myoclonus. Secondary endpoints included the severity of etomidate-induced myoclonus and changes in haemodynamic variables at various time intervals. Additionally, the incidence of adverse effects such as dizziness, bradycardia, hypotension and hallucination were recorded from the administration of esketamine or normal saline to the injection of etomidate.</p><p><strong>Results: </strong>The incidence of myoclonus was significantly lower in Group E (20%) than in Group C (62%). Compared with the control group, the esketamine group also experienced a reduction in the moderate and severe of myoclonus. However, there was no statistically significant difference between the two groups for mild etomidate-induced myoclonus. The haemodynamic data (mean arterial pressure and heart rate) showed no statistically significant differences between two groups at the three time points. The incidence of dizziness, bradycardia, hypotension and hallucination was similar in both groups.</p><p><strong>Conclusion: </strong>Pretreatment with 0.15 mg/kg esketamine prior to anaesthesia induction with etomidate was observed to markedly reduce the incidence and severity of myoclonus, while having no effect on mild etomidate-induced myoclonus and maintaining a stable haemodynamic status.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"5773-5779"},"PeriodicalIF":4.7000,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633297/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of Pretreatment with a Small Dose of Esketamine on Myoclonus Induced by Etomidate: A Randomized Controlled Trial.\",\"authors\":\"Liangliang Gao, Xinyu Lu, Aiping Tan, Jiaying Liufu, Yidan Xu, Lei Wei\",\"doi\":\"10.2147/DDDT.S495130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Etomidate has been observed to precipitate myoclonus in patients undergoing induction of general anaesthesia. This study was designed to investigate the effect of pretreatment with a small dose of esketamine on the incidence of myoclonus induced by etomidate.</p><p><strong>Methods: </strong>One hundred adult patients, who were scheduled to undergo selective operations with general anesthesia, were randomly divided into two groups, with one group receiving esketamine (Group E) and the other receiving normal saline (Group C). The group receiving esketamine (Group E) was administered an injection of 0.15 mg/kg of esketamine, while the control group (Group C) was given an equivalent volume of normal saline two minutes before the administration of 0.3 mg/kg of etomidate. The primary objective was to determine the incidence of etomidate-induced myoclonus. Secondary endpoints included the severity of etomidate-induced myoclonus and changes in haemodynamic variables at various time intervals. Additionally, the incidence of adverse effects such as dizziness, bradycardia, hypotension and hallucination were recorded from the administration of esketamine or normal saline to the injection of etomidate.</p><p><strong>Results: </strong>The incidence of myoclonus was significantly lower in Group E (20%) than in Group C (62%). Compared with the control group, the esketamine group also experienced a reduction in the moderate and severe of myoclonus. However, there was no statistically significant difference between the two groups for mild etomidate-induced myoclonus. The haemodynamic data (mean arterial pressure and heart rate) showed no statistically significant differences between two groups at the three time points. The incidence of dizziness, bradycardia, hypotension and hallucination was similar in both groups.</p><p><strong>Conclusion: </strong>Pretreatment with 0.15 mg/kg esketamine prior to anaesthesia induction with etomidate was observed to markedly reduce the incidence and severity of myoclonus, while having no effect on mild etomidate-induced myoclonus and maintaining a stable haemodynamic status.</p>\",\"PeriodicalId\":11290,\"journal\":{\"name\":\"Drug Design, Development and Therapy\",\"volume\":\"18 \",\"pages\":\"5773-5779\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2024-12-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633297/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Design, Development and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DDDT.S495130\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S495130","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Effect of Pretreatment with a Small Dose of Esketamine on Myoclonus Induced by Etomidate: A Randomized Controlled Trial.
Background: Etomidate has been observed to precipitate myoclonus in patients undergoing induction of general anaesthesia. This study was designed to investigate the effect of pretreatment with a small dose of esketamine on the incidence of myoclonus induced by etomidate.
Methods: One hundred adult patients, who were scheduled to undergo selective operations with general anesthesia, were randomly divided into two groups, with one group receiving esketamine (Group E) and the other receiving normal saline (Group C). The group receiving esketamine (Group E) was administered an injection of 0.15 mg/kg of esketamine, while the control group (Group C) was given an equivalent volume of normal saline two minutes before the administration of 0.3 mg/kg of etomidate. The primary objective was to determine the incidence of etomidate-induced myoclonus. Secondary endpoints included the severity of etomidate-induced myoclonus and changes in haemodynamic variables at various time intervals. Additionally, the incidence of adverse effects such as dizziness, bradycardia, hypotension and hallucination were recorded from the administration of esketamine or normal saline to the injection of etomidate.
Results: The incidence of myoclonus was significantly lower in Group E (20%) than in Group C (62%). Compared with the control group, the esketamine group also experienced a reduction in the moderate and severe of myoclonus. However, there was no statistically significant difference between the two groups for mild etomidate-induced myoclonus. The haemodynamic data (mean arterial pressure and heart rate) showed no statistically significant differences between two groups at the three time points. The incidence of dizziness, bradycardia, hypotension and hallucination was similar in both groups.
Conclusion: Pretreatment with 0.15 mg/kg esketamine prior to anaesthesia induction with etomidate was observed to markedly reduce the incidence and severity of myoclonus, while having no effect on mild etomidate-induced myoclonus and maintaining a stable haemodynamic status.
期刊介绍:
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.